One more acquisition in the news, and a fairly large announcement at that. Just one more indication of the interest and investments from Pharma expanding beyond just drugs and pursuing biotech companies with state of the art technologies for healthcare, this one in the surgical products area. ...
This was somewhat of a first for the US FDA to trust Chinese data. Shenzhen Chipscreen Bio sciences Ltd. was also awarded the Most Valued Partner for Roche R&D Center. Oncology drugs are one of their primary focuses, with individuals trained here in the US and returning to China to create their...
Posted to
The Medical Quack .... by Barbara Duck
on 11-15-2008
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, FDA, Oncology, R and D, China pharma, Chipscreen, biosciences, HUYA
The bar has also risen on Venture Capital money and is harder to get, and so much of the research is still in the “Science” stage, there have been a few companies that have had failed products and just folded up and went away. This certainly leaves the door open for Pharma, who has the financials...
Posted to
The Medical Quack .... by Barbara Duck
on 10-29-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Pharma, Biotech, Science, R and D, Venture Capitalists
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
on 10-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
Recently announced is the project to begin at Scripps in San Diego as related news, coupled with the announcement of the new sequencing service that will be able to offer a complete sequence at a wholesale price may have held a bit of inspiration here for Navigenics to enter the full sequencing market...
Posted to
The Medical Quack .... by Barbara Duck
on 10-16-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, Genomics, Pharma, Biotech, DNA Testing, sequencing services
This is not welcome news by any means for the VC money that was invested. A redirection of the product was too costly as well, thus they shop closes with million invested and a loss. The FDA restrictions also played a role in the limiting of consumer clinical trials here, so with a series...
The group has grown in 7 years from five people focused on healthcare worldwide at Microsoft; now there are more than 700. This group is for responsible primarily for the enterprise space (in biopharma and medical devices), so these are the largest customers in the U.S. I have provided a...
Posted to
The Medical Quack .... by Barbara Duck
on 10-09-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Microsoft/Windows News, personalized medicine, Genomics, healthcare, microsoft, Medical Records, Biotech, R and D, Server 2008, Life Sciences, SharePoint, Windows Presentation Foundation, HPC Server 2008